{"meta":{"query_hash":"f11415678379","filters":{"venue":"Rare Disease and Orphan Drugs Journal"},"cohort_total":4,"direct_labels_cover":0,"predictions_cover":4,"exported":4,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/f11415678379","api":"https://metacan.xera.ac/api/v1/cohort?venue=Rare+Disease+and+Orphan+Drugs+Journal"},"results":[{"id":"W4226226005","doi":"10.20517/rdodj.2022.01","title":"Enhancing the value of clinical networks for rare diseases","year":2022,"lang":"en","type":"article","venue":"Rare Disease and Orphan Drugs Journal","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Standards Association","funders":"","keywords":"Legitimacy; Health care; Knowledge management; Public relations; Diversity (politics); Best practice; Medicine; Political science; Computer science","score_opus":0.0097746278647512,"score_gpt":0.2818339027353585,"score_spread":0.2720592748706073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226226005","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07320685,0.16219632,0.036498014,0.42451912,0.0061829896,0.0011717071,0.0003145013,0.00036140028,0.2955492],"genre_scores_gemma":[0.84501827,0.078678355,0.030455772,0.02988972,0.0027993966,0.00094852684,0.0002369103,0.0001509786,0.011822153],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9423444,0.05034706,0.0012128383,0.0013160836,0.0035257356,0.0012536906],"domain_scores_gemma":[0.8437394,0.1262265,0.0092642335,0.0036096333,0.006851346,0.010308874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.037995335,0.0003903098,0.0005229324,0.0025238912,0.0046074726,0.012481292,0.0022249424,0.0031850107,0.009935498],"category_scores_gemma":[0.09415352,0.0004024649,0.00086917484,0.0018030395,0.0068951477,0.017177595,0.01566151,0.0036748461,0.0011490433],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013005764,0.00016257283,0.008031731,0.011535152,0.00020337598,0.0023348716,0.09894094,0.0009972793,0.0007352898,0.20649979,0.05934466,0.6110843],"study_design_scores_gemma":[0.00007128315,0.00025259663,0.005277148,0.020537764,0.00015791784,0.0019360792,0.045575354,0.0005937944,0.0005248164,0.06954377,0.85545266,0.00007684171],"about_ca_topic_score_codex":0.0017664043,"about_ca_topic_score_gemma":0.0042843637,"teacher_disagreement_score":0.037995335,"about_ca_system_score_codex":0.0073899627,"about_ca_system_score_gemma":0.019032061,"threshold_uncertainty_score":0.20094097},"labels":[],"label_agreement":null},{"id":"W4367019825","doi":"10.20517/rdodj.2023.04","title":"Sustainable approaches for drug repurposing in rare diseases: recommendations from the IRDiRC Task Force","year":2023,"lang":"en","type":"article","venue":"Rare Disease and Orphan Drugs Journal","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadiana.org","funders":"","keywords":"Repurposing; Drug repositioning; Identification (biology); Medicine; Sustainability; Task (project management); Task force; Drug development; Business; Drug; Pharmacology; Engineering; Political science","score_opus":0.04927013266708733,"score_gpt":0.33548942283619226,"score_spread":0.2862192901691049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367019825","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018769214,0.04890143,0.009357738,0.9083041,0.010602259,0.0026061367,0.0007539165,0.00052515353,0.017072354],"genre_scores_gemma":[0.028046828,0.1484956,0.25899637,0.4976355,0.009068057,0.017424399,0.0054459525,0.0007524364,0.034134813],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.90367985,0.04144724,0.01521757,0.0031269495,0.023166405,0.013362049],"domain_scores_gemma":[0.7559246,0.103050336,0.014931224,0.0073066377,0.090040326,0.02874682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.17443006,0.0035471253,0.004094034,0.0099415425,0.007145417,0.0144304205,0.015464708,0.039613996,0.009937122],"category_scores_gemma":[0.106435,0.0019990592,0.007507635,0.0069722,0.008177418,0.012793205,0.01819965,0.02942113,0.0077587073],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013050046,0.0012365831,0.0024618686,0.0098982,0.000099517914,0.0010745623,0.004618166,0.0019212102,0.0015192445,0.018973043,0.75206023,0.20600681],"study_design_scores_gemma":[0.00016744177,0.00023569066,0.0030958627,0.036002517,0.000136601,0.00045148138,0.0069118724,0.0008735534,0.00047061074,0.009618325,0.94180804,0.00022792675],"about_ca_topic_score_codex":0.044406526,"about_ca_topic_score_gemma":0.038313597,"teacher_disagreement_score":0.17443006,"about_ca_system_score_codex":0.014886575,"about_ca_system_score_gemma":0.17667699,"threshold_uncertainty_score":0.92248535},"labels":[],"label_agreement":null},{"id":"W4400098184","doi":"10.20517/rdodj.2024.14","title":"Longitudinal biomarker evaluation in Fabry disease patients receiving lentivirus-mediated gene therapy","year":2024,"lang":"en","type":"article","venue":"Rare Disease and Orphan Drugs Journal","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Fleurimont","funders":"","keywords":"Globotriaosylceramide; Fabry disease; Enzyme replacement therapy; Genetic enhancement; Medicine; Biomarker; Urine; Internal medicine; Alpha-galactosidase; Urology; Disease; Gastroenterology; Oncology; Gene; Biology","score_opus":0.036504650923119136,"score_gpt":0.3265417238837958,"score_spread":0.2900370729606767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400098184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984792,0.000616674,0.00017924437,0.000051162115,0.0000048976685,0.000041296127,0.00024051951,0.000009170859,0.00037784167],"genre_scores_gemma":[0.9985863,0.0001976895,0.0003427117,0.00008101015,0.0000050218264,0.000027257629,0.00041543503,0.0000018311821,0.00034275334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996146,0.00007394732,0.000019832449,0.00007397433,0.00012877148,0.0000888594],"domain_scores_gemma":[0.9992894,0.000048606624,0.00021968319,0.000027063646,0.00026506608,0.00015015191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011222878,0.00023750165,0.0004277978,0.00054158195,0.0008294015,0.00064772594,0.00029924922,0.00035463105,0.00051157066],"category_scores_gemma":[0.0010489288,0.00011219975,0.00024154766,0.00066657463,0.00023448546,0.00023269992,0.00026348463,0.00046209455,0.000121394325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013897432,0.00020656391,0.9784572,0.00003470786,0.000065849876,0.00020327361,0.00042679347,0.00007143309,0.007643172,0.000026215188,0.00025448753,0.011220563],"study_design_scores_gemma":[0.000020583517,0.0014880705,0.99429953,0.000013104383,0.0000715414,0.00028255722,0.00031845507,0.00022163242,0.002173604,0.000022365664,0.0010798032,0.000008702735],"about_ca_topic_score_codex":0.031444084,"about_ca_topic_score_gemma":0.036826592,"teacher_disagreement_score":0.031444084,"about_ca_system_score_codex":0.0013502642,"about_ca_system_score_gemma":0.0014204577,"threshold_uncertainty_score":0.06252211},"labels":[],"label_agreement":null},{"id":"W4400570519","doi":"10.20517/rdodj.2023.61","title":"Fabry nephropathy: a treatable cause of chronic kidney disease","year":2024,"lang":"en","type":"article","venue":"Rare Disease and Orphan Drugs Journal","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Globotriaosylceramide; Medicine; Fabry disease; Enzyme replacement therapy; Proteinuria; Albuminuria; Nephropathy; Kidney disease; Alpha-galactosidase; Internal medicine; Podocyte; Cardiomyopathy; Dialysis; Glomerular basement membrane; Kidney; Disease; Heart failure; Pathology; Urology; Endocrinology; Diabetes mellitus","score_opus":0.01343904179696902,"score_gpt":0.29033695014167454,"score_spread":0.2768979083447055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400570519","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16332154,0.74463034,0.012614293,0.018319374,0.0016487989,0.00031908695,0.0018441088,0.0011236629,0.056178756],"genre_scores_gemma":[0.7480804,0.21260412,0.0053269593,0.007783416,0.0025535189,0.00018769751,0.0025987707,0.00008129725,0.020783883],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99976355,0.000044171804,0.000016677031,0.00003655112,0.00006894747,0.000070033166],"domain_scores_gemma":[0.99986815,0.000018249697,0.000032576572,0.000007637032,0.000025985786,0.00004735792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003104805,0.00042586753,0.0008728831,0.00047733236,0.0006363749,0.0005221502,0.00046145078,0.0008763908,0.0038863886],"category_scores_gemma":[0.00047791444,0.00006544161,0.0003222048,0.00066651584,0.00022337634,0.00027822296,0.00056600757,0.0007006377,0.0012282793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008918391,0.00082907977,0.03939544,0.004131175,0.0003911055,0.040996403,0.00038936417,0.0005291087,0.01888173,0.0070577874,0.1015997,0.7849073],"study_design_scores_gemma":[0.0003811705,0.0011625737,0.09448082,0.004165809,0.0008416871,0.22866473,0.0005734339,0.001372146,0.006292833,0.009661253,0.6523194,0.000084141095],"about_ca_topic_score_codex":0.0017117334,"about_ca_topic_score_gemma":0.0014250171,"teacher_disagreement_score":0.0038863886,"about_ca_system_score_codex":0.0005486965,"about_ca_system_score_gemma":0.0006928579,"threshold_uncertainty_score":0.013001323},"labels":[],"label_agreement":null}]}